CEO & PresidentRead More
Mr. Bash has 23 years of strategic and operational leadership experience, managing businesses, building teams and launching products that have helped improve patients’ lives across a number of therapeutic areas. He joins Checkmate from Bristol Myers Squibb (BMS), where he most recently served as Senior Vice President, Commercial Model Innovation, and prior to that, Senior Vice President, Commercial for Immunology and Fibrosis, partnering with Research & Development to advance early and late-stage assets in the integrated BMS and Celgene portfolios. Mr. Bash has a deep expertise in immuno-oncology, having led the U.S. launch of the PD-1 checkpoint inhibitor, Opdivo; serving as franchise lead for metastatic melanoma; and leading the launch of the first FDA-approved checkpoint combination. He also served as Worldwide Vice President for BMS’s lung cancer franchise and led the product team for a targeted treatment for head and neck cancer and colorectal cancer. During his tenure at BMS, he was a champion for talent development, served as co-chair of the diversity and inclusion council, and was the executive sponsor for Women in Immunology. Mr. Bash earned his BA from Georgetown University and his MBA from Columbia Business School.
James Wooldridge, MD
Chief Medical OfficerRead More
Jim has more than 20 years of drug development experience in academia, pharma, and biotech. He received an MD from Tulane University, and completed his post-graduate training in Internal Medicine and Medical Oncology at the University of Iowa, after which he conducted clinical and translational cancer research on the faculties of the University of Missouri in Columbia and the University of Iowa. While at the University of Iowa, he performed some of the first pre-clinical cancer experiments in mice with CpG oligos and designed and conducted an early CpG oligo clinical trial. Prior to joining Checkmate, Dr. Wooldridge served as Chief Medical Officer at Aeglea BioTherapeutics, where he oversaw development programs in oncology and rare genetic diseases, including pegzilarginase, which received Breakthrough Designation for Arginase 1 Deficiency. He spent 11 years in cancer research at Eli Lilly and Company, where he led Oncology US Medical Affairs and more recently served as the Chief Scientific Officer for Immuno-oncology Clinical Development.
Chief Financial OfficerRead More
Rob brings to Checkmate more than 20 years of experience as a life sciences financial executive driving the strategy, planning, execution, and financing of private and public biopharmaceutical companies. He joins Checkmate from Akcea Therapeutics where he served as Vice President, Finance, leading accounting operations, SEC reporting, financial planning and treasury activities. He previously held various financial leadership roles at Moderna Therapeutics, Forum Pharmaceuticals, Inc., and Human Genome Sciences, Inc., after starting his career in the biopharma industry at Amgen, Inc. He received an MBA from The Wharton School and a BS in civil engineering and strategic management from the University of Pennsylvania.
Art Krieg, MD
Founder, Chief Scientific OfficerRead More
Art has worked in the oligonucleotide field since the 1980s. After discovering immune stimulatory CpG DNA in 1994, he co-founded Coley Pharmaceutical Group in 1997 to develop the technology, discovering and taking 4 novel CpG oligonucleotides into clinical development. In 2008, Pfizer acquired Coley, and Art became Chief Scientific Officer of Pfizer’s Oligonucleotide Therapeutics Unit until they exited the field in 2011. Art subsequently co-founded RaNA Therapeutics, serving as its CEO through 2013, and served as CSO at Sarepta Therapeutics until July 2014. He co-founded the first antisense journal, Nucleic Acid Therapeutics, and the Oligonucleotide Therapeutic Society, for which he recently served as President. Art received an MD from Washington University and trained in internal medicine at the University of Minnesota and in rheumatology at the NIH before joining the faculty at the University of Iowa, becoming professor of internal medicine. He has published more than 250 scientific papers and is an inventor on >50 issued US patents covering oligonucleotide technologies.
Kleem Chaudhary, PhD
Chief Business OfficerRead More
Kleem brings to Checkmate more than 18 years of experience within the biotech/pharma industry with broad experience across business development & licensing, strategy and drug discovery. He has held leadership roles of increasing responsibility across multiple organizations including most recently as Head of Business Development & Licensing at Biogen and previously as a transaction leader in Business Development at Takeda. He began his business development career at Novartis, where he was a team leader and led deals across multiple therapeutic areas. Prior to Novartis, he was a medicinal chemist at Gilead Sciences. Kleem holds a PhD in chemistry from the University of North Carolina at Chapel Hill and a BSc in chemistry from the University of Winnipeg.
General CounselRead More
Katherine is a seasoned legal and business executive with more than 19 years of experience advising public companies on significant corporate transactions, corporate governance and capital markets, including a dozen years in the life sciences industry. She serves as a member of the board of directors of Harvard Bioscience, where she is the chair of its governance committee and a member of the audit committee. Prior to joining Checkmate, Ms. Eade was Vice President, Strategic Commercial Affairs at Align Technology, and she previously served as the Director, M&A Law and Transactions for Corning Incorporated and Division Counsel for Corning’s Life Sciences and Pharmaceutical Technologies divisions. She began her legal career at Cleary Gottlieb, a leading international law firm, and she served as a law clerk for Judge Morton I. Greenberg of the U.S. Court of Appeals for the Third Circuit. She received a JD, cum laude, from Harvard Law School and a BA in government, summa cum laude, from Cornell University.